首页 › 基金 › Frazier Life Sciences Management, L.P. › XLO
Frazier Life Sciences Management, L.P. 对 XLO 的持仓历史
XILIO THERAPEUTICS INC · 医疗保健
Frazier Life Sciences Management, L.P. 在 Q2 2026 的 13F 申报中披露持有 XLO(XILIO THERAPEUTICS INC)422,505 股,市值约 US$4.0M,约占其申报组合的 0.09%,在其申报持仓中市值排名第 40 位。 Frazier Life Sciences Management, L.P. 最近 3 个申报季度中有 3 个季度披露了 XLO 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Frazier Life Sciences Management, L.P. 对 XLO 的持仓演变
Frazier Life Sciences Management, L.P. 于 Q4 2025 首次披露 XLO 持仓:5,915,091 股(约 US$3.8M)。 该持仓在 Q2 2026 达到峰值 422,505 股,市值约 US$4.0M。 在 3 次申报中,Frazier Life Sciences Management, L.P. 0 次增持、1 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 422,505 股、市值约 US$4.0M。 持仓曾出现大幅变动:Q1 2026 减持约 93% (随后一个季度股价上涨 14%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 5.92M | $3.79M | 新进 |
| Q1 2026 | 422.50K | $3.55M | 减持 |
| Q2 2026 | 422.50K | $4.05M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 XLO 与 13F 数据
XLO(XILIO THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 24 只申报持有 XLO,申报仓位最大的包括:Bain Capital Life Sciences Investors, LLC (US$6.4M), GILEAD SCIENCES, INC. (US$6.2M), Stonepine Capital Management, LLC (US$2.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 XLO 的基金
- Bain Capital Life Sciences Investors, LLC 664.02K 股 · $6.36M · Q2 2026
- GILEAD SCIENCES, INC. 650.39K 股 · $6.23M · Q2 2026
- Stonepine Capital Management, LLC 225.99K 股 · $2.17M · Q2 2026
- Sio Capital Management, LLC 152.46K 股 · $1.46M · Q2 2026
- Merck & Co., Inc. 105.98K 股 · $1.02M · Q2 2026
- AJU IB Investment Co., Ltd. 47.70K 股 · $401.12K · Q1 2026
- Velan Capital Investment Management LP 14.29K 股 · $136.85K · Q2 2026
更多关于 Frazier Life Sciences Management, L.P.
常见问题
How long has Frazier Life Sciences Management, L.P. held XLO?
Frazier Life Sciences Management, L.P. has disclosed XLO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Frazier Life Sciences Management, L.P.'s current position in XLO?
As of Q2 2026, Frazier Life Sciences Management, L.P. holds 422.50K shares of XLO (XILIO THERAPEUTICS INC), valued at $4.05M, representing 0.09% of its reported portfolio and ranking #40.
Has Frazier Life Sciences Management, L.P. been buying or selling XLO?
In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in XLO. The position peaked in Q2 2026 at 422.50K shares.
Which other funds hold XLO?
Other major institutional holders of XLO include Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., Stonepine Capital Management, LLC, among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.